Published in Cancer Res on March 01, 1995
Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J Clin Invest (2003) 16.67
Autophagy and human diseases. Cell Res (2013) 2.17
Role and regulation of autophagy in cancer. Biochim Biophys Acta (2009) 2.00
Autophagy as a therapeutic target in cancer. Cancer Biol Ther (2011) 1.84
Autophagy and cancer. Exp Mol Med (2012) 1.57
Genetic and epigenetic silencing of the beclin 1 gene in sporadic breast tumors. BMC Cancer (2010) 1.20
Absence of 185delAG mutation of the BRCA1 gene and 6174delT mutation of the BRCA2 gene in Ashkenazi Jewish men with prostate cancer. Br J Cancer (1998) 1.16
Tumor focality in prostate cancer: implications for focal therapy. Nat Rev Clin Oncol (2010) 1.09
Beclin 1 deficiency is associated with increased hypoxia-induced angiogenesis. Autophagy (2011) 1.06
Characterization of six tumor suppressor genes and microsatellite instability in hepatocellular carcinoma in southern African blacks. World J Gastroenterol (1999) 1.01
Common mutations in BRCA1 and BRCA2 do not contribute to early prostate cancer in Jewish men. Prostate (1999) 1.01
Autophagy is active in normal colon mucosa. Autophagy (2012) 0.96
Microsatellite instability and loss of heterozygosity in human pterygia. Br J Ophthalmol (1997) 0.94
Fine-mapping the HOXB region detects common variants tagging a rare coding allele: evidence for synthetic association in prostate cancer. PLoS Genet (2014) 0.93
The PEA-15 protein regulates autophagy via activation of JNK. J Biol Chem (2010) 0.92
Allelic loss detected on chromosomes 8, 10, and 17 by fluorescence in situ hybridization using single-copy P1 probes on isolated nuclei from paraffin-embedded prostate tumors. Am J Pathol (1997) 0.92
BRCA1 loss preexisting in small subpopulations of prostate cancer is associated with advanced disease and metastatic spread to lymph nodes and peripheral blood. Clin Cancer Res (2010) 0.90
Targeting autophagy in cancer management - strategies and developments. Cancer Manag Res (2015) 0.89
Autophagy paradox and ceramide. Biochim Biophys Acta (2013) 0.89
Clinical relevance of genetic instability in prostatic cells obtained by prostatic massage in early prostate cancer. Br J Cancer (2005) 0.87
Ceramide induced mitophagy and tumor suppression. Biochim Biophys Acta (2015) 0.84
Allelic Losses from Chromosome 17 in Human Osteosarcomas. Pathol Oncol Res (1997) 0.83
Prognostic significance of the allelic loss of the BRCA1 gene in colorectal cancer. Gut (2003) 0.83
Molecular detection of tumour DNA in serum and peritoneal fluid from ovarian cancer patients. Br J Cancer (1999) 0.82
Beclin 1 deficiency correlated with lymph node metastasis, predicts a distinct outcome in intrahepatic and extrahepatic cholangiocarcinoma. PLoS One (2013) 0.82
Loss of heterozygosity (LOH), malignancy grade and clonality in microdissected prostate cancer. Br J Cancer (1999) 0.81
Roles of autophagy induced by natural compounds in prostate cancer. Biomed Res Int (2015) 0.80
Autophagy in hepatocellular carcinomas: from pathophysiology to therapeutic response. Hepat Med (2016) 0.79
Rarity of microsatellite alterations in acute myeloid leukaemia. Br J Cancer (1996) 0.79
Papillary carcinoma of the breast in a male patient with a treated prostatic carcinoma diagnosed by fine-needle aspiration biopsy: a case report and review of the literature. Diagn Cytopathol (2006) 0.79
Genetics of prostate cancer. Clin Med Res (2003) 0.79
The autophagy GABARAPL1 gene is epigenetically regulated in breast cancer models. BMC Cancer (2015) 0.78
P53 tumour-suppressor gene mutations are mainly localised on exon 7 in human primary and metastatic prostate cancer. Br J Cancer (1996) 0.78
Downregulation of Beclin 1 and impairment of autophagy in a small population of colorectal cancer. Dig Dis Sci (2013) 0.78
Beclin-1 expression is retained in high-grade serous ovarian cancer yet is not essential for autophagy induction in vitro. J Ovarian Res (2015) 0.77
Recessive oncogenes: current status. Pathol Oncol Res (1995) 0.77
Increased ATG5-ATG12 in hepatitis B virus-associated hepatocellular carcinoma and their role in apoptosis. World J Gastroenterol (2016) 0.75
The role of autophagy in hepatocellular carcinoma: friend or foe. Oncotarget (2017) 0.75
High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo (1995) 3.25
Neoadjuvant hormonal downsizing of localized carcinoma of the prostate: effects on the volume of normal tissue irradiation. Cancer Invest (1995) 2.90
Extraskeletal osteosarcoma. A clinicopathologic review of 26 cases. Cancer (1990) 2.56
Interobserver reproducibility of Gleason grading of prostatic carcinoma: urologic pathologists. Hum Pathol (2001) 2.31
Mixed epithelial and stromal tumor of the kidney. Am J Surg Pathol (2000) 2.24
Prognostic implications of a positive apical margin in radical prostatectomy specimens. J Urol (1997) 1.83
Degradation of extracellular-matrix proteins by human cathepsin B from normal and tumour tissues. Biochem J (1992) 1.79
Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med (2000) 1.67
Prostacyclin: a potent antimetastatic agent. Science (1981) 1.58
Chromosomal analysis of renal angiomyolipoma by comparative genomic hybridization: evidence for clonal origin. Hum Pathol (1999) 1.57
Recursive partitioning for prognostic grouping of patients with clinically localized prostate carcinoma. Cancer (2000) 1.50
Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone. Cancer Res (1999) 1.48
Does hyperbaric oxygen have a cancer-causing or -promoting effect? A review of the pertinent literature. Undersea Hyperb Med (1994) 1.47
Age and racial distribution of prostatic intraepithelial neoplasia. Eur Urol (1996) 1.46
A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. Eur J Cancer (1991) 1.44
Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy. Cancer Epidemiol Biomarkers Prev (2001) 1.43
Lysosomal cathepsin B: correlation with metastatic potential. Science (1981) 1.43
Hormone-refractory prostate cancer cells express functional follicle-stimulating hormone receptor (FSHR). J Urol (1999) 1.42
Current status of tissue markers as prognostic factors in prostatic adenocarcinoma. Int J Radiat Oncol Biol Phys (1995) 1.41
Palliative irradiation for bone metastasis--a new paradigm. Int J Radiat Oncol Biol Phys (1994) 1.40
Anti-CD3/anti-CD28 monoclonal antibody-coated suture enhances the immune response of patients with head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg (1999) 1.40
Acute non-lymphocytic leukaemia and myelofibrosis following sequential hemibody irradiation for prostatic carcinoma. Clin Oncol (R Coll Radiol) (1991) 1.40
Evidence for three tumor suppressor gene loci on chromosome 8p in human prostate cancer. Cancer Res (1995) 1.38
P504S immunohistochemical detection in 405 prostatic specimens including 376 18-gauge needle biopsies. Am J Surg Pathol (2002) 1.33
Platelet-type 12-lipoxygenase in a human prostate carcinoma stimulates angiogenesis and tumor growth. Cancer Res (1998) 1.33
Arachidonate lipoxygenases as essential regulators of cell survival and apoptosis. Proc Natl Acad Sci U S A (1996) 1.33
High flow malignant priapism with isolated metastasis to the corpora cavernosa. Urology (1998) 1.31
Concurrent angiomyolipoma and renal cell neoplasia: a study of 36 cases. Mod Pathol (2001) 1.31
Morphological study of the interaction of intravascular tumor cells with endothelial cells and subendothelial matrix. Cancer Res (1988) 1.29
Cathepsin B: association with plasma membrane in metastatic tumors. Proc Natl Acad Sci U S A (1986) 1.29
Prostate secretory protein (PSP94) suppresses the growth of androgen-independent prostate cancer cell line (PC3) and xenografts by inducing apoptosis. Prostate (1999) 1.26
Outcome of African American men screened for prostate cancer: the Detroit Education and Early Detection Study. J Urol (1997) 1.24
Cathepsin B activity in B16 melanoma cells: a possible marker for metastatic potential. Cancer Res (1982) 1.24
Allelic loss in locally metastatic, multisampled prostate cancer. Cancer Res (1994) 1.24
Mechanism of the stimulation of prostaglandin H synthase and prostacyclin synthase by the antithrombotic and antimetastatic agent, nafazatrom. Mol Pharmacol (1984) 1.22
Prostacyclin and thromboxanes. Implications for their role in tumor cell metastasis. Biochem Pharmacol (1983) 1.21
Malignant peripheral nerve sheath tumor (malignant schwannoma) of urinary bladder in von Recklinghausen neurofibromatosis. Urology (1991) 1.20
Interactions of cancer cells with the microvasculature during metastasis. FASEB J (1988) 1.20
Target to apoptosis: a hopeful weapon for prostate cancer. Prostate (1997) 1.19
Cysteine proteinases and metastasis. Cancer Metastasis Rev (1984) 1.18
Prostaglandins and cancer: a review of tumor initiation through tumor metastasis. Prostaglandins (1981) 1.18
Bone marrow stromal cells upregulate expression of bone morphogenetic proteins 2 and 4, gap junction protein connexin-43 and synaptophysin after stroke in rats. Neuroscience (2006) 1.18
College of American Pathologists Conference XXXV: solid tumor prognostic factors-which, how and so what? Summary document and recommendations for implementation. Cancer Committee and Conference Participants. Arch Pathol Lab Med (2000) 1.17
Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. Clin Cancer Res (2001) 1.17
Role of eicosanoids in prostate cancer progression. Cancer Metastasis Rev (2001) 1.16
Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. J Urol (1998) 1.16
Fetal bovine serum: a multivariate standard. Proc Soc Exp Biol Med (1975) 1.15
Elevated 12-lipoxygenase mRNA expression correlates with advanced stage and poor differentiation of human prostate cancer. Urology (1995) 1.14
Eicosanoid regulation of angiogenesis: role of endothelial arachidonate 12-lipoxygenase. Blood (2000) 1.13
Combination cisplatin, 5-fluorouracil and radiation therapy for locally advanced unresectable or medically unfit bladder cancer cases: a Southwest Oncology Group Study. J Urol (2001) 1.13
Frequent loss of expression and loss of heterozygosity of the putative tumor suppressor gene DCC in prostatic carcinomas. Cancer Res (1993) 1.13
Arrest and extravasation of B16 amelanotic melanoma in murine lungs. A light and electron microscopic study. Lab Invest (1985) 1.13
Thromboxane A(2) regulation of endothelial cell migration, angiogenesis, and tumor metastasis. Biochem Biophys Res Commun (2000) 1.12
Interactions between cancer cells and the microvasculature: a rate-regulator for metastasis. Clin Exp Metastasis (1989) 1.12
Gleason score 7 prostate cancer: a heterogeneous entity? Correlation with pathologic parameters and disease-free survival. Urology (2000) 1.11
Properties of a plasma membrane-associated cathepsin B-like cysteine proteinase in metastatic B16 melanoma variants. Cancer Res (1987) 1.11
Focal xanthogranulomatous pyelonephritis presenting as a renal tumor with vena caval thrombus. J Urol (1998) 1.10
The prostatic capsule: does it exist? Its importance in the staging and treatment of prostatic carcinoma. Am J Surg Pathol (1989) 1.10
College of American Pathologists Conference XXVI on clinical relevance of prognostic markers in solid tumors. Summary. Members of the Cancer Committee. Arch Pathol Lab Med (1995) 1.10
Bidirectional control of membrane expression and/or activation of the tumor cell IRGpIIb/IIIa receptor and tumor cell adhesion by lipoxygenase products of arachidonic acid and linoleic acid. Cancer Res (1989) 1.08
Lipoxygenase metabolites of arachidonic and linoleic acids modulate the adhesion of tumor cells to endothelium via regulation of protein kinase C. Cell Regul (1991) 1.08
Epidemiology of high grade prostatic intraepithelial neoplasia. Pathol Res Pract (1995) 1.07
Sarcomatoid renal cell carcinoma. An immunohistochemical study of 18 cases. Arch Pathol Lab Med (1993) 1.06
High levels of tissue inhibitor of metalloproteinase-2 (TIMP-2) expression are associated with poor outcome in invasive bladder cancer. Cancer Res (1996) 1.05
Blue nevus and melanosis of the prostate. Electron-microscopic and immunohistochemical studies. Am J Clin Pathol (1988) 1.05
Mixed epithelial and stromal tumor of the kidney lacks the genetic alterations of cellular congenital mesoblastic nephroma. Hum Pathol (2001) 1.05
Vascular endothelial growth factor mediates atorvastatin-induced mammalian achaete-scute homologue-1 gene expression and neuronal differentiation after stroke in retired breeder rats. Neuroscience (2006) 1.04
12-Lipoxygenase, 12(S)-HETE, and cancer metastasis. Ann N Y Acad Sci (1994) 1.04
Grading the invasive component of urothelial carcinoma of the bladder and its relationship with progression-free survival. Am J Surg Pathol (2000) 1.04
Extended survivability of prostate cancer cells in the absence of trophic factors: increased proliferation, evasion of apoptosis, and the role of apoptosis proteins. Cancer Res (1998) 1.03
Endogenous 12(S)-HETE production by tumor cells and its role in metastasis. Cancer Res (1994) 1.03
Niaspan reduces high-mobility group box 1/receptor for advanced glycation endproducts after stroke in type-1 diabetic rats. Neuroscience (2011) 1.03
12(S)-HETE is a mitogenic factor for microvascular endothelial cells: its potential role in angiogenesis. Biochem Biophys Res Commun (1995) 1.03
Degradation of laminin by human tumor cathepsin B. Clin Exp Metastasis (1989) 1.03
Thrombin increases the metastatic potential of tumor cells. Int J Cancer (1993) 1.02
Prostate cancer DNA ploidy and response to salvage hormone therapy after radiotherapy with or without short-term total androgen blockade: an analysis of RTOG 8610. J Clin Oncol (2003) 1.02
Updated protocol for the examination of specimens from patients with carcinomas of the prostate gland: a basis for checklists. Cancer Committee. Arch Pathol Lab Med (2000) 1.01
Biosynthesis of 12(S)-hydroxyeicosatetraenoic acid by B16 amelanotic melanoma cells is a determinant of their metastatic potential. Lab Invest (1994) 1.01
Expression of inflammatory modulator COX-2 in pancreatic ductal adenocarcinoma and its relationship to pathologic and clinical parameters. Am J Clin Oncol (2001) 1.01
Should the age specific prostate specific antigen cutoff for prostate biopsy be higher for black than for white men older than 50 years? J Urol (2000) 1.01
Lymph node size does not correlate with the presence of prostate cancer metastasis. Urology (1999) 1.01
Membrane type 1-matrix metalloproteinase (MT1-MMP) and MMP-2 immunolocalization in human prostate: change in cellular localization associated with high-grade prostatic intraepithelial neoplasia. Clin Cancer Res (1999) 1.01
Usefulness of immunoperoxidase staining with high-molecular-weight cytokeratin in the differential diagnosis of small-acinar lesions of the prostate gland. Virchows Arch A Pathol Anat Histopathol (1990) 0.99
Cyclooxygenase, lipoxygenase and tumor angiogenesis. Cell Mol Life Sci (2002) 0.99
Involvement of the multiple tumor suppressor genes and 12-lipoxygenase in human prostate cancer. Therapeutic implications. Adv Exp Med Biol (1997) 0.99
Radiotherapeutic management of osseous metastases: a survey of current patterns of care. Int J Radiat Oncol Biol Phys (1998) 0.99
Neutron or photon irradiation for prostate tumors: enhancement of cytokine therapy in a metastatic tumor model. Clin Cancer Res (2001) 0.99
12(S)-hydroxyeicosatetraenoic acid and 13(S)-hydroxyoctadecadienoic acid regulation of protein kinase C-alpha in melanoma cells: role of receptor-mediated hydrolysis of inositol phospholipids. Proc Natl Acad Sci U S A (1995) 0.99